Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases
Completed
- Conditions
- CancerSolid Tumor
- Registration Number
- NCT01248429
- Lead Sponsor
- Centre Oscar Lambret
- Brief Summary
This study describes the elevation of CPK in patient treated for solid tumors by TKI
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 154
Inclusion Criteria
- Patients with solid tumor treated by inhibitor of tyrosin kinase for at least 1 week
- Patient examined AND with a routine blood test planned
- Patient informed of procedure for the study who was not opposed to it
Exclusion Criteria
- Patient treated for malignant hemopathy
- Patient no treated by inhibitor of thyrosine kinase or for less than 1 week
- Patients with no routine blood laboratory tests planned
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the prevalence of the CPK increase Within 3 days after a clinical exam Dosage of CPK during standard blood sampling. The increase of CPK is defined when CPK value \> USL
- Secondary Outcome Measures
Name Time Method Correlation myalgia/CPK increase During the clinical exam To determine the correlation between myalgia and CPK blood, taking into account the risk factors leading to CPK increase
Trial Locations
- Locations (27)
Centre Paul Papin
🇫🇷Angers, France
Hôpital Jean Minjoz
🇫🇷Besancon, France
CHU Bordeaux
🇫🇷Bordeaux, France
Institut Bergonié
🇫🇷Bordeaux, France
Centre François Baclesse
🇫🇷Caen, France
Centre Jean Perrin
🇫🇷Clermont Ferrand, France
Hôpital Henri Mondor - APHP
🇫🇷Creteil, France
Centre Oscar Lambret
🇫🇷Lille, France
CHU Limoges
🇫🇷Limoges, France
Hôpital Edouard Herriot
🇫🇷Lyon, France
Scroll for more (17 remaining)Centre Paul Papin🇫🇷Angers, France